Allogene Therapeutics (ALLO) Investor presntation - Slideshow

Company Overview - Allogene has treated over 175 patients with AlloCAR T™ product candidates, more than any other allogeneic CAR T company[3] - The company held $637 million in cash, cash equivalents, and investments as of September 30, 2022[3] - Allogene operates a fully-integrated GMP facility with a projected capacity of approximately 20,000 patients annually[65] Clinical Programs & Data - Approximately 97% of patients treated with ALLO-501/ALLO-501A received treatment within 2-5 days of study enrollment[43] - The 6-month Complete Response (CR) rate for ALLO-501/501A in LBCL (mITT) was in the range of high 20s to 40%[43] - In the UNIVERSAL trial, approximately 90% of patients were treated within 5 days of study enrollment, obviating the need for bridging therapy[47] - In the UNIVERSAL trial, a 71% overall response rate and 46% VGPR+ was observed at the 320M cell dose of ALLO-715[48] - 92% of VGPR+ responses were MRD negative in the UNIVERSAL trial[48] Pipeline & Future Development - Allogene plans to initiate a potentially pivotal Phase 2 trial of ALLO-501A in r/r LBCL in mid-2022[64] - The company is developing ALLO-316, a CD70-targeted AlloCAR T for solid tumors, currently in Phase 1 (TRAVERSE trial)[65] - Doses from 40 million to 360 million cells are being tested in the TRAVERSE trial[60]